BASDAI tends to be higher in women while there is no appreciable difference in ASDAS scoring in men compared to women. Dr. L. Eder believes this could be due to the pain scoring in both indices. #RNL2024 @RheumNow @lihi_eder https://t.co/i7XPenrmGG

Did you know the majority of lecturers at #RNL2024 are women? #StrongWomenLeaders @ACRheum #RNL2024 #WomenChangingLives @rheumnow https://t.co/0TO8XUhhg5

With regard to SpA patient journey: On average, women are diagnosed 2.3 years later than men. Additionally, women tend to have more visits to rheumatology to reach diagnosis of PsA, AS, and RA! Remember your inherent bias along with sex/gender disparities. Dr. L. Eder… https://t.co/o0Hv3NrXpB https://t.co/vsMN3HkSv6

Did you know? There is very limited reporting of sex-disaggregated RCT results, data necessary from an FDA standpoint. Dr. L. Eder points out the importance of this data from a clinical standpoint. Let's do better! #RNL2024 @RheumNow @lihi_eder https://t.co/3FETZZWt0B

This is the risk. We have to be aware and better at this in order to serve our female patients better @lihi_eder @RheumNow #RNL2024 https://t.co/7JIDtlSGXh

The panel addresses the question about using combination biologics and combo tsDMARDS + biologic. These combos are being studied. The panel noted combo apremilast +biologic is pretty commonly used appears to be effective and safe. #RNL2024 @rheumnow https://t.co/EeIlhJiDZU

Dr. Eder noted in her metanalysis of treatment efficacy in PsA based on gender – women had poorer response to treatments; the placebo effects are the same between men and women, suggesting a biologic mechanism and rather than a “psychosomatic” effect. #RNL2024 @rheumnow https://t.co/3H2Nfamg70

My volume of referrals for OCI or degenerative disease (or sometimes completely normal SI joints) read as "sacroiliiitis" really does seem to have been increasing lately @lihi_eder @RheumNow #RNL2024 https://t.co/vksNCaADck

👉“Eighty percent of drugs withdrawn from the market pose greater risk for women.” – Dr. Eder #RNL2024 @rheumnow #genderDifferences https://t.co/RZrIdvecbY

Welcome to the "FDA-approved" team Bimekizumab. Dr. Armstrong shows MOA of IL17a and IL17f dual inhibition, and the important PASI scores showing 2/3 of pts clear by week 16. @RheumNow #RNL2024 @_AprilArmstrong https://t.co/KiTcVsGzpD

Dr. April Armstrong shares a beautiful picture around pathophysiology in PsO/PsA, as demonstrated in a non-joint graphic below. "Consider the domains when choosing biologics." #RNL2024 @RheumNow @_AprilArmstrong https://t.co/2nUAUYZLL3

The different outcomes and response to treatment in males and females are related to sex differences in pain mechanisms and gender roles. Women report a higher BASDAI level, the ASDAS is equal in both sexes, Lihi Eder #RNL2024 @RheumNow https://t.co/7jjkgmmUg8